
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+4
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimers and Parkinsons disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinsons Disease, Alzheimers disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation JJDC, Inc. (JJDC) and...
Orphan diseases,tauopathies,alzheimer's disease,small molecule drug discovery,neurodegeneration,novel therapeutics,psp,parkinson's disease,and biotechnology
Asceneuron sa operates in the Biotechnology research industry.
Asceneuron sa's revenue is 1m - 10m
Asceneuron sa has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.